You searched for "tear"
What's trending Aug/Sep 2023
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #Trufflesthekitty #Visionambassador #glassescat #ambylopiaawarness Truffles the Kitty was recently featured on Good Morning America [1]. Save the cute kitty footage for...Animal antics for children with vision impairment
Nine families with children with vision impairment got up to some animal antics at a mini zoo in Perth, thanks to the charity RNIB.Crisis Collection Day sees volunteers’ success
Crisis at Christmas collection day saw 130 pairs of specs lined up to be dispensed to very grateful Londoners experiencing homelessness. Ranging in powers from +5D to -15.25D, the dispensing day brought together volunteers who have worked to provide eyecare...World-class centre for eye health reaches construction milestone
The new home for Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology reached a significant construction milestone today. The completion of the concrete structure as part of the new centre for advancing eye health in St...Ocular Melanoma UK launches Ocular Melanoma October to shine a light on rare eye cancer
Ocular Melanoma UK (OMUK) the nation’s only charity dedicated exclusively to supporting those affected by ocular melanoma, today launched Ocular Melanoma October – a nationwide campaign highlighting the realities of living with this rare, life-threatening and often misunderstood cancer. Each...
Outcomes of ‘treat and extend’ for neovascular AMD
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
